vs

Side-by-side financial comparison of MATRIX SERVICE CO (MTRX) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

MATRIX SERVICE CO is the larger business by last-quarter revenue ($210.5M vs $207.3M, roughly 1.0× Ultragenyx Pharmaceutical Inc.). MATRIX SERVICE CO runs the higher net margin — -0.4% vs -62.0%, a 61.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 12.5%). MATRIX SERVICE CO produced more free cash flow last quarter ($6.3M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 12.6%).

Matrix Telecom, Inc., operating as Matrix Business Technologies, Trinsic, Powered by Matrix, Excel Telecommunications and various other niche brands is a United States telecommunications firm that provides voice and data services to consumers and small and medium businesses as well as multi-location distributed enterprise markets. The firm also provides wholesale voice services to the telecommunications, wireless and cable industries.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

MTRX vs RARE — Head-to-Head

Bigger by revenue
MTRX
MTRX
1.0× larger
MTRX
$210.5M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+13.4% gap
RARE
25.9%
12.5%
MTRX
Higher net margin
MTRX
MTRX
61.6% more per $
MTRX
-0.4%
-62.0%
RARE
More free cash flow
MTRX
MTRX
$107.0M more FCF
MTRX
$6.3M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
12.6%
MTRX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
MTRX
MTRX
RARE
RARE
Revenue
$210.5M
$207.3M
Net Profit
$-894.0K
$-128.6M
Gross Margin
6.2%
Operating Margin
-1.0%
-54.7%
Net Margin
-0.4%
-62.0%
Revenue YoY
12.5%
25.9%
Net Profit YoY
83.8%
3.5%
EPS (diluted)
$-0.03
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MTRX
MTRX
RARE
RARE
Q4 25
$210.5M
$207.3M
Q3 25
$211.9M
$159.9M
Q2 25
$216.4M
$166.5M
Q1 25
$200.2M
$139.3M
Q4 24
$187.2M
$164.6M
Q3 24
$165.6M
$139.5M
Q2 24
$189.5M
$147.0M
Q1 24
$166.0M
$108.8M
Net Profit
MTRX
MTRX
RARE
RARE
Q4 25
$-894.0K
$-128.6M
Q3 25
$-3.7M
$-180.4M
Q2 25
$-11.3M
$-115.0M
Q1 25
$-3.4M
$-151.1M
Q4 24
$-5.5M
$-133.2M
Q3 24
$-9.2M
$-133.5M
Q2 24
$-4.4M
$-131.6M
Q1 24
$-14.6M
$-170.7M
Gross Margin
MTRX
MTRX
RARE
RARE
Q4 25
6.2%
Q3 25
6.7%
Q2 25
3.8%
Q1 25
6.4%
Q4 24
5.8%
Q3 24
4.7%
Q2 24
6.6%
Q1 24
3.4%
Operating Margin
MTRX
MTRX
RARE
RARE
Q4 25
-1.0%
-54.7%
Q3 25
-2.6%
-106.9%
Q2 25
-6.0%
-64.8%
Q1 25
-2.5%
-102.6%
Q4 24
-3.4%
-74.3%
Q3 24
-6.5%
-94.6%
Q2 24
-2.8%
-79.1%
Q1 24
-8.7%
-151.9%
Net Margin
MTRX
MTRX
RARE
RARE
Q4 25
-0.4%
-62.0%
Q3 25
-1.7%
-112.8%
Q2 25
-5.2%
-69.0%
Q1 25
-1.7%
-108.5%
Q4 24
-3.0%
-80.9%
Q3 24
-5.6%
-95.7%
Q2 24
-2.3%
-89.5%
Q1 24
-8.8%
-156.8%
EPS (diluted)
MTRX
MTRX
RARE
RARE
Q4 25
$-0.03
$-1.28
Q3 25
$-0.13
$-1.81
Q2 25
$-0.41
$-1.17
Q1 25
$-0.12
$-1.57
Q4 24
$-0.20
$-1.34
Q3 24
$-0.33
$-1.40
Q2 24
$-0.16
$-1.52
Q1 24
$-0.53
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MTRX
MTRX
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$199.0M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$137.6M
$-80.0M
Total Assets
$650.2M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MTRX
MTRX
RARE
RARE
Q4 25
$199.0M
$421.0M
Q3 25
$192.3M
$202.5M
Q2 25
$224.6M
$176.3M
Q1 25
$185.5M
$127.1M
Q4 24
$156.8M
$174.0M
Q3 24
$124.6M
$150.6M
Q2 24
$115.6M
$480.7M
Q1 24
$69.7M
$112.3M
Stockholders' Equity
MTRX
MTRX
RARE
RARE
Q4 25
$137.6M
$-80.0M
Q3 25
$136.3M
$9.2M
Q2 25
$142.7M
$151.3M
Q1 25
$150.7M
$144.2M
Q4 24
$151.9M
$255.0M
Q3 24
$156.5M
$346.8M
Q2 24
$164.2M
$432.4M
Q1 24
$165.8M
$140.3M
Total Assets
MTRX
MTRX
RARE
RARE
Q4 25
$650.2M
$1.5B
Q3 25
$598.2M
$1.2B
Q2 25
$600.3M
$1.3B
Q1 25
$613.7M
$1.3B
Q4 24
$513.8M
$1.5B
Q3 24
$470.2M
$1.5B
Q2 24
$451.4M
$1.6B
Q1 24
$440.0M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MTRX
MTRX
RARE
RARE
Operating Cash FlowLast quarter
$7.5M
$-99.8M
Free Cash FlowOCF − Capex
$6.3M
$-100.8M
FCF MarginFCF / Revenue
3.0%
-48.6%
Capex IntensityCapex / Revenue
0.6%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$45.5M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MTRX
MTRX
RARE
RARE
Q4 25
$7.5M
$-99.8M
Q3 25
$-25.9M
$-91.4M
Q2 25
$40.7M
$-108.3M
Q1 25
$31.2M
$-166.5M
Q4 24
$33.6M
$-79.3M
Q3 24
$11.9M
$-67.0M
Q2 24
$47.0M
$-77.0M
Q1 24
$24.8M
$-190.7M
Free Cash Flow
MTRX
MTRX
RARE
RARE
Q4 25
$6.3M
$-100.8M
Q3 25
$-27.9M
$-92.7M
Q2 25
$38.4M
$-110.7M
Q1 25
$28.7M
$-167.8M
Q4 24
$32.7M
$-79.5M
Q3 24
$10.0M
$-68.6M
Q2 24
$45.7M
$-79.0M
Q1 24
$20.0M
$-193.9M
FCF Margin
MTRX
MTRX
RARE
RARE
Q4 25
3.0%
-48.6%
Q3 25
-13.2%
-58.0%
Q2 25
17.8%
-66.5%
Q1 25
14.3%
-120.5%
Q4 24
17.5%
-48.3%
Q3 24
6.0%
-49.2%
Q2 24
24.1%
-53.7%
Q1 24
12.1%
-178.2%
Capex Intensity
MTRX
MTRX
RARE
RARE
Q4 25
0.6%
0.5%
Q3 25
0.9%
0.8%
Q2 25
1.0%
1.5%
Q1 25
1.3%
1.0%
Q4 24
0.5%
0.1%
Q3 24
1.2%
1.2%
Q2 24
0.7%
1.4%
Q1 24
2.9%
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MTRX
MTRX

Storage And Terminal Solutions$99.9M47%
Utility And Power Infrastructure$75.4M36%
Process And Industrial Facilities$35.3M17%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons